BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REM-422 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REM-422\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06297941-2976@assetmemo.bio
DTSTAMP:20261121T005427Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:REM-422: Phase 1 readout est. (NCT06297941)
DESCRIPTION:REM-422\, phase 1\, Acute Myeloid Leukemia.\nStudy: Study of RE
 M-422 in Patients With AML or Higher Risk MDS\nEstimated primary completio
 n: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rem-
 422#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06297941
URL:https://assetmemo.bio/drug/rem-422#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118086-2976@assetmemo.bio
DTSTAMP:20261121T005427Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:REM-422: Phase 1/2 readout est. (NCT06118086)
DESCRIPTION:REM-422\, phase 1/2.\nStudy: Study of REM-422 in Patients With 
 Recurrent\, Metastatic\, or Unresectable Adenoid Cystic Carcinoma\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/rem-422#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06118086
URL:https://assetmemo.bio/drug/rem-422#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
